GlassScriptPhysician profile
Batool Q Mir
NPI 1366482937
$14,153.03
in general payments reported to CMS, 2019-2025
49 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,613 · 2020: $2,747 · 2021: $2,299 · 2022: $2,451 · 2023: $2,174 · 2024: $1,543 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,028 · Education: $15.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,028.09 |
| Education | $15.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,294.71 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,751.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $1,579.49 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,126.11 | 2021-2024 | |
| Lilly USA, LLC | $839.22 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $835.82 | 2019-2024 | |
| Glaxosmithkline, LLC. | $767.38 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $578.35 | 2019-2023 | |
| Amarin Pharma, INC. | $537.70 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.71 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $369.37 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Teva Pharmaceuticals USA, INC. | $273.79 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $264.12 | 2021-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.44 | 2022-2024 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $181.62 | 2020-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Batool Mir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.